The use of bisphosphonates in men with hormonerefractory prostate cancer: a systematic review of randomized trials
Scott Berry1, Tricia Waldron2, Eric Winquist3, Himu Lukka4,
on behalf of the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group5
Canadian Journal of Urology, Vol.13, No.4, pp. 3180-3188, 2006
Abstract Purpose: A systematic review of randomized controlled trials (RCTs) was performed to assess the benefits of bisphosphonate therapy in men with hormone-refractory prostate cancer (HRPC).
Methods: The literature was searched to identify RCTs or meta-analyses comparing treatment with bisphosphonates to placebo or no treatment.
Results: Ten trials that studied clodronate (five trials, 404 patients), pamidronate (two trials, 350 patients), alendronate (one trial, 49 patients), etidronate (one trial, 51 patients), and zoledronic acid (one trial, 643 patients) in men with HRPC and bone metastases met the eligibility criteria. Pain response was the most frequently reported primary outcome (eight… More >